BeOne Medicines (ONC) Deferred Taxes (2017 - 2023)
BeOne Medicines (ONC) posted quarterly Deferred Taxes of -$46000.0 for Q4 2023, down 102.74% year-over-year from $1.7 million in Q4 2022, and down 106.13% quarter-over-quarter from $750000.0 in Q3 2023.
BeOne Medicines (ONC) Deferred Taxes (2017 - 2023) Analysis & Trends
BeOne Medicines (ONC) has reported Deferred Taxes for 7 consecutive years, with -$46000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Deferred Taxes fell 102.74% year-over-year to -$46000.0; the TTM figure through Dec 2023 stood at $689000.0 (down 66.54% YoY), while the FY2025 annual figure was $9.5 million, down 63.56% from the prior year.
- Deferred Taxes fell to -$46000.0 in Q4 2023 per ONC's latest filing, from $750000.0 in the prior quarter.
- Across five years, Deferred Taxes topped out at $14.8 million in Q3 2021 and bottomed at -$12.3 million in Q1 2021.
- Historically, Deferred Taxes has averaged -$142300.0 across 5 years, with a median of -$48500.0 in 2023.
- Annual changes were most pronounced in 2021 — Deferred Taxes sank 5847.09% — and 2022, when it jumped 941.67%.
- BeOne Medicines' Deferred Taxes stood at $4.1 million in 2019, then soared by 119.97% to $9.0 million in 2020, then tumbled by 89.99% to $903000.0 in 2021, then soared by 85.94% to $1.7 million in 2022, then tumbled by 102.74% to -$46000.0 in 2023.
- Business Quant data shows ONC's Deferred Taxes at -$46000.0 in Q4 2023, $750000.0 in Q3 2023, and -$51000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -137,876.64 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.66 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -46,000.00 |
| Sep 30, 2023 | 750,000.00 |
| Jun 30, 2023 | -51,000.00 |
| Mar 31, 2023 | 36,000.00 |
| Dec 31, 2022 | 1.68 Mn |
| Sep 30, 2022 | -175,000.00 |
| Jun 30, 2022 | 505,000.00 |
| Mar 31, 2022 | 50,000.00 |
| Dec 31, 2021 | 903,000.00 |
| Sep 30, 2021 | 14.79 Mn |
| Jun 30, 2021 | -60,000.00 |
| Mar 31, 2021 | -12.25 Mn |
| Dec 31, 2020 | 9.02 Mn |
| Sep 30, 2020 | -7.70 Mn |
| Jun 30, 2020 | -854,000.00 |
| Mar 31, 2020 | -206,000.00 |
| Dec 31, 2019 | 4.10 Mn |
| Sep 30, 2019 | -11.88 Mn |
| Jun 30, 2019 | -473,000.00 |
| Mar 31, 2019 | -983,000.00 |